The FDA panel voted 7-4 with one abstention that the safety data of Pfizer’s RSV vaccine are adequate for approval in people 60 & up, according to multiple reports of the advisory committee meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold
- FDA Virtual Vaccines & Related Biological Products Advisory Committee Meeting
- Seagen price target raised to $210 from $180 at Oppenheimer
- Pfizer acquisition of Seagen could add $7B in sales, says JPMorgan
- Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says